Peptides Of 3 To 100 Amino Acid Residues Patents (Class 530/300)
Thymopoietin or lipotropin; related peptides (Class 530/301)
Endorphin and enkephalin; related peptides (Class 530/302)
Insulin; related peptides (Class 530/303)
Corticotropin (atch); related peptides (Class 530/306)
Calcitonin; related peptides (Class 530/307)
Glucagon; related peptides (Class 530/308)
Secretin or gastrin; related peptides (Class 530/309)
Gramicidin or tyrocidin; related peptides (Class 530/310)
Somatostatin (srif); related peptides (Class 530/311)
Melanotropin (msh) or eledoisin; related peptides (Class 530/312)
Lutenizing hormone releasing factor (lrf); related peptides (Class 530/313)
Bradykinin; kallidin; related peptides (Class 530/314)
Oxytocin; vasopressin; related peptides (Class 530/315)
Angiotensin; related peptides (Class 530/316)
Cyclic peptides (Class 530/317)
Peptides containing saccharide radicals, e.g., bleomycins, etc. (Class 530/322)
Peptides with at least one nonpeptide bond other than a disulfide bond joining two or more sequences of amino acid residues, e.g., homomeric heterodectic peptide other than cyclic disulfide, depsipeptides, etc. (Class 530/323)
25 or more amino acid residues in defined sequence (Class 530/324)
24 amino acid residues in defined sequence (Class 530/325)
15 to 23 amino acid residues in defined sequence (Class 530/326)
11 to 14 amino acid residues in defined sequence (Class 530/327)
8 to 10 amino acid residues in defined sequence (Class 530/328)
6 to 7 amino acid residues in defined sequence (Class 530/329)
4 to 5 amino acid residues in defined sequence (Class 530/330)
Tripeptides, e.g., tripeptide thyroliberin (trh), melanostatin (mif), etc. (Class 530/331)
Containing at least one abnormal peptide link, e.g., gamma peptide bonded, etc. (Class 530/332)
Synthesis of peptides (Class 530/333)
Separation or purification (Class 530/344)
Chemical aftertreatment, e.g., acylation, methylation, etc. (Class 530/345)
  • SELECTIVE ANTICANCER CHIMERIC PEPTIDE
    Publication number: 20130274201
    Abstract: It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
    Type: Application
    Filed: April 5, 2013
    Publication date: October 17, 2013
    Inventors: Koji Kawakami, Masayuki Kohno, Tomohisa Horibe, Oumi Nakajima, Mari Haramoto, Liying Yang
  • Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides
    Patent number: 8557955
    Abstract: The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 7, 8, 9, 10, 11, 12, 192, 195, 197, 209, 225, 226, 228, 230, 240, 241, 243, 244, 249, 253, 254 or 255, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted, deleted, or added, wherein the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with the over-expression of MPHOSPH1 and/or DEPDC1, e.g. cancers, containing these peptides as an active ingredient. The peptides of the present invention can also be used as vaccines.
    Type: Grant
    Filed: October 16, 2007
    Date of Patent: October 15, 2013
    Assignee: OncoTherapy Science, Inc.
    Inventors: Tomoaki Fujioka, Yusuke Nakamura, Takuya Tsunoda, Ryuji Osawa, Midori Shida
  • Polypeptides having glucoamylase activity and polynucleotides encoding same
    Patent number: 8557541
    Abstract: The present invention relates to isolated polypeptides having glucoamylase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Grant
    Filed: November 30, 2010
    Date of Patent: October 15, 2013
    Assignees: Novozymes A/S, Novozymes North America, Inc
    Inventors: Sara Landvik, Marc D. Morant, Keiichi Ayabe, Guillermo Coward-Kelly
  • Aligned polymers including bonded substrates
    Patent number: 8557956
    Abstract: The present disclosure relates to the present disclosure relates to a method of fabricating an aligned polymer containing a bonded substrate and related compositions. The method involved placing a polymer in solution which is capable of alignment wherein the polymer is also bound to a selected substrate. This may then be followed by placing the polymer solution in an electrochemical cell wherein the polymer solution is in contact with at least one electrode and applying an electric field/voltage to the polymer solution and generating a pH gradient wherein the polymer and bonded substrate positions at the isoelectric point of the polymer in solution.
    Type: Grant
    Filed: June 11, 2010
    Date of Patent: October 15, 2013
    Assignee: Southwest Research Institute
    Inventors: Xingguo Cheng, Vasiliki Z. Poenitzsch
  • EFGR antibodies comprising modular recognition domains
    Patent number: 8557243
    Abstract: Antibodies containing one or more modular recognition domains (MRDs) that can be used to target the antibodies to specific sites are described. The use of antibodies containing one or more modular recognition domains to treat disease, and methods of making antibodies containing one or more modular recognition domains are also described.
    Type: Grant
    Filed: July 14, 2011
    Date of Patent: October 15, 2013
    Assignee: The Scripps Research Institute
    Inventor: Carlos F. Barbas, III
  • Methods of treating disorders by administration of F11 receptor antagonists
    Patent number: 8557957
    Abstract: The present invention provides a compound including a peptidomimetic which interacts sterically with the binding site of a F11R molecule, the peptidomimetic including a peptidomimetic having the SEQ ID NO: 4D. The present invention also provides a method for treating a disorder comprising administering peptide 4D to a mammal.
    Type: Grant
    Filed: June 9, 2011
    Date of Patent: October 15, 2013
    Inventors: Elizabeth Kornecki, Anna Babinska, Yigal H. Ehrlich
  • Peptide for augmenting and expression of BDNF and pharmaceutical composition for prevention and treatment of neurodegenerative diseases including Alzheimer's disease or Parkinson's disease, comprising the same
    Patent number: 8557960
    Abstract: Disclosed are peptides for augmenting the expression of BDNF (brain-derived neurotrophic factor) and a pharmaceutical composition for the prevention and treatment of Alzheimer's disease or Parkinson's disease, comprising the same. The peptides can induce the expression of BDNF in dopamine-reactive human cells, pass easily through the blood-brain barrier thanks to their low molecular weights and are almost free of cytotoxicity. Thus, they are useful in the prevention and treatment of neuropathies such as Alzheimer's disease or Parkinson's disease.
    Type: Grant
    Filed: December 31, 2009
    Date of Patent: October 15, 2013
    Assignee: Sungkyunkwan University
    Inventors: Kil Lyong Kim, Hong Gi Kim, Woo Ram Jung, Dong Ik Park, Min Kyoo Shin
  • Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
    Patent number: 8557781
    Abstract: Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a wide range of possible functionalities, but typical have at least one aromatic amine group. Also disclosed herein are non-natural amino acid polypeptides that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such polypeptides. Typically, the modified non-natural amino acid polypeptides include at least one alkylated amine group. Further disclosed are methods for using such non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, including therapeutic, diagnostic, and other biotechnology uses.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: October 15, 2013
    Assignee: AMBRX, Inc.
    Inventors: Zhenwei Miao, Junjie Liu, Thea Norman
  • Compositions having antiangiogenic activity and uses thereof
    Patent number: 8557772
    Abstract: Compositions and methods that are useful for modulating blood vessel formation, as well as methods that provide for the systematic and efficient identification of angiogenesis modulators are described. As discussed in more detail below, a systematic computational methodology based on bioinformatics was used to identify novel peptide modulators of angiogenesis that have been characterized in vitro and/or in vivo.
    Type: Grant
    Filed: February 8, 2012
    Date of Patent: October 15, 2013
    Assignee: The Johns Hopkins University
    Inventors: Aleksander S. Popel, Emmanouil D. Karagiannis
  • Luminescent 1-hydroxy-2-pyridinone chelates of lanthanides
    Patent number: 8557601
    Abstract: The present invention provides luminescent complexes between a lanthanide ion and an organic ligand which contains 1,2-hydroxypyridinone units. The complexes of the invention are stable in aqueous solutions and are useful as molecular probes, for example in medical diagnostics and bioanalytical assay systems. The invention also provides methods of using the complexes of the invention.
    Type: Grant
    Filed: July 10, 2007
    Date of Patent: October 15, 2013
    Assignee: The Regents of the University of California
    Inventors: Kenneth N. Raymond, Jide Xu, Evan G. Moore, Eric J. Werner
  • Recombinant proteins having haemostatic activity and capable of inducing platelet aggregation
    Patent number: 8557774
    Abstract: Disclosed herein are recombinant proteins capable of inducing platelet aggregation and uses thereof.
    Type: Grant
    Filed: September 22, 2009
    Date of Patent: October 15, 2013
    Assignee: Centre Hospitalier Universitaire de
    Inventors: David Vandroux, Emmanuel De Maistre, Edouard Prost
  • ERBB2 antibodies comprising modular recognition domains
    Patent number: 8557242
    Abstract: Antibodies containing one or more modular recognition domains (MRDs) that can be used to target the antibodies to specific sites are described. The use of antibodies containing one or more modular recognition domains to treat disease, and methods of making antibodies containing one or more modular recognition domains are also described.
    Type: Grant
    Filed: July 14, 2011
    Date of Patent: October 15, 2013
    Assignee: The Scripps Research Institute
    Inventor: Carlos F. Barbas, III
  • BIOACTIVE FUS1 PEPTIDES AND NANOPARTICLE-POLYPEPTIDE COMPLEXES
    Publication number: 20130266634
    Abstract: A nanoparticle-polypeptide complex comprising a bioactive polypeptide in association with a nanoparticle, wherein the bioactive polypeptide is modified by the addition of a chemical moiety that facilitates cellular uptake of the protein. The polypeptide can be a protein or a peptide. In some embodiments, the amino acid sequence of the protein or peptide is derived from the amino acid sequence of a tumor suppressor gene product.
    Type: Application
    Filed: December 19, 2012
    Publication date: October 10, 2013
    Inventors: Jacki LIN, Ralph ARLINGHAUS, Tong SUN, Lin JI, Bulent OZPOLAT, Gabriel LOPEZ-BERESTEIN, Jack A. ROTH
  • ARTIFICIAL ANTIBODY POLYPEPTIDES
    Publication number: 20130267676
    Abstract: The present invention provides a fibronectin type III (Fn3) molecule, wherein the Fn3 contains a stabilizing mutation. The present invention also provides Fn3 polypeptide monobodies, nucleic acid molecules encoding monobodies, and variegated nucleic acid libraries encoding such monobodies. Also provided are methods of preparing a Fn3 polypeptide monobody, and kits to perform the methods.
    Type: Application
    Filed: August 2, 2012
    Publication date: October 10, 2013
    Inventor: Shohei Koide
  • Molecular Markers for the Diagnosis and Treatment of Tumors
    Publication number: 20130266936
    Abstract: The invention relates to the diagnosis, prognosis, monitoring, and treatment of neoplastic diseases such as tumor diseases, especially tumor diseases of the endometrium and the metastases thereof.
    Type: Application
    Filed: December 20, 2012
    Publication date: October 10, 2013
    Inventors: Eric STEINER, Jan HENGSTLER, Jens Sagemüller
  • MICROFLUIDIC FLUID SEPARATOR AND RELATED METHODS
    Publication number: 20130267005
    Abstract: A microfluidic fluid separator for separating target components of a fluid by filtration is described. Methods for separating target components of a fluid by filtration and methods for processing blood on a large scale with the microfluidic fluid separator are provided.
    Type: Application
    Filed: June 7, 2013
    Publication date: October 10, 2013
    Inventors: Emil P. KARTALOV, Axel SCHERER, Koichi SAYANO
  • SOX9 INHIBITORS
    Publication number: 20130266663
    Abstract: Methods for treating a condition associated with proteoglycan production in a mammal are provided. The methods comprise the administration of at least one of a calmodulin antagonist, a transient receptor potential (TRP) channel inhibitor and a calmodulin-binding peptide to the mammal.
    Type: Application
    Filed: April 29, 2011
    Publication date: October 10, 2013
    Inventors: Arthur Brown, Sandy Gian Vascotto
  • Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides
    Patent number: 8552146
    Abstract: The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 7, 8, 9, 10, 11, 12, 192, 195, 197, 209, 225, 226, 228, 230, 240, 241, 243, 244, 249, 253, 254 or 255, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted, deleted, or added, wherein the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with the over-expression of MPHOSPH1 and/or DEPDC1, e.g. cancers, containing these peptides as an active ingredient. The peptides of the present invention can also be used as vaccines.
    Type: Grant
    Filed: July 30, 2012
    Date of Patent: October 8, 2013
    Assignee: OncoTherapy Science, Inc.
    Inventors: Tomoaki Fujioka, Yusuke Nakamura, Takuya Tsunoda, Ryuji Osawa, Midori Shida
  • Targeting vector-phospholipid conjugates
    Patent number: 8551450
    Abstract: Peptide vectors having high KDR binding affinity and processes for making such vectors are provided. The peptide vectors may be conjugated to phospholipids and included in ultrasound contrast agent compositions. Such ultrasound contrast agents are particularly useful in therapeutic and diagnostic methods, such as in imaging KDR-containing tissue and in the evaluation and treatment of angiogenic processes associated with neoplastic conditions. The present invention also provides processes for the large scale production of highly pure dimeric and monomeric peptide phospholipid conjugates as well as precursor materials used to form the conjugates. The present invention further provides processes for the large scale production of highly pure peptide phospholipid conjugates which contain very low levels of TFA.
    Type: Grant
    Filed: May 19, 2010
    Date of Patent: October 8, 2013
    Inventors: Philippe Bussat, Samir Cherkaoui, Hong (Helen) Fan, Bernard Lamy, Palaniappa Nanjappan, Radhakrishna Pillai, Sibylle Pochon, Bo Song, Rolf E. Swenson
  • Endotoxin detection method
    Patent number: 8551719
    Abstract: The invention relates to a method for detecting endotoxins in a sample.
    Type: Grant
    Filed: February 20, 2013
    Date of Patent: October 8, 2013
    Assignee: Hyglos Invest GmbH
    Inventors: Roman Meyer, Michael Schütz, Holger Grallert, Renate Grassl, Stefan Miller
  • TNF-? antagonists containing IGFBP5
    Patent number: 8552148
    Abstract: The present invention relates to: TNF-? antagonists containing IGFBP5 protein, variants thereof, or fragments thereof; and the use of the TNF-? antagonists. More specifically, the present invention relates to: a polynucleotide encoding the protein, variants thereof, or fragments thereof; a vector containing the polynucleotide; a transformant containing the vector; and a method for screening a therapeutic agent for TNF-? overexpression-related diseases by checking whether the mutual reaction thereof is facilitated after treating with candidates to the cell expressing the IGFBP5 protein, variants thereof, or fragments thereof, and the TNFR1.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: October 8, 2013
    Assignee: Sungkyunkwan University Foundation For Corporate Collaboration
    Inventors: Je-Ho Lee, Jae-Ryoung Hwang, Jae-Ho Huh
  • Peptide having an extending action for half-life of object peptide in plasma
    Patent number: 8551937
    Abstract: An isolated chimeric peptide consisting of one or two added peptides and an object peptide wherein the added peptide is bonded to the N-terminus, the C-terminus or both of the object peptide, wherein if the added peptides are bound to both terminals, the two added peptides may be the same or different; and physiological activity of the object peptide is still retained, wherein the object peptide is a natural physiologically active peptide selected from the group consisting of an atrial natriuretic peptide, a brain natriuretic peptide, a C-type natriuretic peptide, motilin, a glucagon-like peptide 1, parathyroid hormone, and calcitonin, or a derivative of any thereof, wherein the derivative has one or more amino acid(s) deleted from the amino acid sequence of a natural physiologically active peptide and has the desired physiological activity.
    Type: Grant
    Filed: May 22, 2009
    Date of Patent: October 8, 2013
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Naomi Wakabayashi, Seiji Sato
  • Frizzled-binding agents and their use in screening for WNT inhibitors
    Patent number: 8551789
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and other polypeptides, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided. Screening methods are also provided.
    Type: Grant
    Filed: April 1, 2011
    Date of Patent: October 8, 2013
    Assignee: OncoMed Pharmaceuticals
    Inventor: Austin L. Gurney
  • Vaccine peptide combinations against cat allergy
    Patent number: 8551492
    Abstract: The present invention relates to compositions comprising peptides for preventing or treating allergy to cats, and in particular to optimal combinations of peptides.
    Type: Grant
    Filed: May 30, 2008
    Date of Patent: October 8, 2013
    Assignee: Circassia Limited
    Inventors: Roderick Peter Hafner, Mark Larche, Anthony Barrington Kay
  • Vaccine for modulating between T1 and T2 immune responses
    Patent number: 8552145
    Abstract: The present invention provides liposomal vaccines containing immunogenic lipopeptides that are capable of modulating the humoral and cellular immune responses in vivo.
    Type: Grant
    Filed: May 2, 2012
    Date of Patent: October 8, 2013
    Assignee: Oncothyreon Inc.
    Inventors: Wladyslaw A. Budzynski, R. Rao Koganty, Mark J. Krantz, B. Michael Longenecker
  • Pharmaceutical preparations and methods for inhibiting tumors
    Patent number: 8551951
    Abstract: The invention provides pharmaceutical compositions and method for inhibiting growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH). In one embodiment the pharmaceutical composition includes human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof. In another embodiment, the pharmaceutical composition includes a mixture of human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof and an anticancer drug which may be administered in an appropriate dosage form, dosage quantity and dosage regimen to a patient suffering from, for example of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, benign prostate hyperplasia, or (BPH) gastrointestinal cancer.
    Type: Grant
    Filed: January 22, 2010
    Date of Patent: October 8, 2013
    Assignee: Aenorasis SA Pharmaceuticals and Medical Devices
    Inventors: Seema Garde, Chandra J. Panchal, Madhulika Baijal-Gupta, Jennifer Fraser, Salam Kadhim
  • Peptide with reduced dimer formation
    Patent number: 8551493
    Abstract: The present invention relates to peptides which are formulated or engineered to prevent or reduce the formation of dimers.
    Type: Grant
    Filed: August 15, 2008
    Date of Patent: October 8, 2013
    Assignee: Circassia Limited
    Inventors: Roderick Peter Hafner, Paul Laidler
  • Compositions and methods for modulating dopamine neurotransmission
    Patent number: 8552152
    Abstract: The present invention provides for diagnosis or treatment of neurological or neuropsychiatric disorders involving abnormal dopamine neurotransmission. Methods and agents are provided for modulating dopamine transporter activity and modulating dopaminergic neurotransmission. Agents of the present invention include fragments of D2 receptor or dopamine transporter (DAT) that can disrupt D2-DAT coupling.
    Type: Grant
    Filed: October 5, 2012
    Date of Patent: October 8, 2013
    Assignee: Centre for Addiction and Mental Health
    Inventor: Fang Liu
  • NPR-B agonists
    Patent number: 8551938
    Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.
    Type: Grant
    Filed: September 23, 2010
    Date of Patent: October 8, 2013
    Assignee: Alcon Research, Ltd.
    Inventors: Mark R. Hellberg, Iok-Hou Pang
  • Methods for treatment of pain
    Patent number: 8551949
    Abstract: The invention provides for methods and compositions for treatment of pain via craniofacial mucosal administration of an analgesic compound (e.g. a non-opioid analgesic peptide, an NOP agonist or N/OFQ). Intranasal administration of certain analgesic peptides such as N/OFQ results in global analgesic effects.
    Type: Grant
    Filed: July 27, 2010
    Date of Patent: October 8, 2013
    Assignee: Nocicepta LLC
    Inventors: Lawrence R. Toll, David C. Yeomans, Martin S. Angst, Daniel I. Jacobs
  • RADIOCONJUGATION METHOD
    Publication number: 20130259803
    Abstract: The present invention relates to the field of radiopharmaceuticals for in vivo imaging, in particular to a method of labelling a biological targeting molecule with a radioisotope. The method of the invention is particularly suitable for use with an automated synthesizer apparatus. Also provided are precursors in sterile form, as well as cassettes comprising such precursors useful in the method.
    Type: Application
    Filed: December 1, 2011
    Publication date: October 3, 2013
    Applicant: GE HEALTHCARE LIMITED
    Inventor: Bard Indrevoll
  • TFPI INHIBITORS AND METHODS OF USE
    Publication number: 20130259863
    Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.
    Type: Application
    Filed: March 18, 2013
    Publication date: October 3, 2013
    Inventors: Michael Dockal, Rudolf Hartmann, Markus Fries, Friedrich Scheiflinger, Hartmut Ehrlich, Ulrich Reineke, Frank Osterkamp, Thomas Polakowski
  • GLUTAMINE-RICH PEPTIDES AS AIR ENTRAINING AGENTS IN BUILDING MATERIAL COMPOUNDS
    Publication number: 20130255541
    Abstract: The use of hydrolysates of glutamine-rich proteins for use as air entraining agents in building material compounds.
    Type: Application
    Filed: April 2, 2013
    Publication date: October 3, 2013
    Applicant: Evonik Industries AG
    Inventors: Martin SCHILLING, Christoph Toelle, Ralph Scheuermann, Sabine Giessler-Blank, Jörn Heißing
  • COMPOSITIONS, METHODS AND USES FOR STIMULATING IMMUNE RESPONSES
    Publication number: 20130259826
    Abstract: Embodiments herein report compositions, methods and uses for inducing an innate immune response in a subject. Embodiments herein also generally report compositions, methods and uses for bacterial-derived peptides to induce an innate immune response in a subject having a bacterial or viral disorder and/or cancer. In certain embodiments, compositions herein concern derivatives of p60 protein of Listeria monocytogenes.
    Type: Application
    Filed: November 10, 2010
    Publication date: October 3, 2013
    Inventors: Laurel L. Lenz, Rebecca L. Schmidt
  • Tuberculosis vaccine with improved efficacy
    Patent number: 8545854
    Abstract: The present invention relates to novel recombinant vaccines providing protective immunity against tuberculosis. Further, the present invention refers to novel recombinant nucleic acid molecules, vectors containing said nucleic acid molecules, cells transformed with said nucleic acid molecules and polypeptides encoded by said nucleic acid molecules.
    Type: Grant
    Filed: June 22, 2011
    Date of Patent: October 1, 2013
    Assignee: Max-Planck-Gesellschaft zur Foerderung der Wissenshaften, e.V.
    Inventors: Leander Grode, Stefan H. E. Kaufmann, Baerbel Raupach, Juergen Hess
  • NPR-B agonists
    Patent number: 8546523
    Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.
    Type: Grant
    Filed: September 23, 2010
    Date of Patent: October 1, 2013
    Assignee: Alcon Research, Ltd.
    Inventors: Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Uwe Richter, Bernadett Simon, Edgar Specker, Markus Woischnik, Mark R. Hellberg
  • Transport agents for crossing the blood-brain barrier and into brain cancer cells and methods of use thereof
    Patent number: 8545812
    Abstract: The present invention discloses methods and materials for delivering a cargo compound into a brain cancer cell and/or across the blood-brain barrier. Delivery of the cargo compound is accomplished by the use of protein transport peptides derived from Neisseria outer membrane proteins, such as Laz. The invention also provides synthetic transit peptides comprised of the pentapeptide AAEAP. The invention further discloses methods for treating cancer, and specifically brain cancer, as well as other brain-related conditions. Further, the invention provides methods of imaging and diagnosing cancer, particular brain cancer.
    Type: Grant
    Filed: May 25, 2012
    Date of Patent: October 1, 2013
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Chang Soo Hong, Tohru Yamada, Arsenio M. Fialho, Tapas K. Das Gupta, Ananda M. Chakrabarty
  • Chimeric human beta defensins
    Patent number: 8546525
    Abstract: The invention relates to a nucleic acid molecule selected from the group comprising a) a nucleic acid molecule having one of the nucleotide sequences presented in SEQ ID:NO 4 to SEQ ID:NO 8, b) a nucleic acid molecule that codes for a peptide having one of the amino acid sequences presented in SEQ ID:NO 12 to SEQ ID:NO 16, c) a nucleic acid molecule, the complementary strand of which hybridizes to a nucleic acid molecule according to a) or b) and which codes for a peptide having antimicrobial activity, and d) a nucleic acid molecule, the nucleotide sequence of which deviates from the nucleotide sequence of a nucleic acid molecule according to c) because of the degenerated genetic code.
    Type: Grant
    Filed: November 20, 2010
    Date of Patent: October 1, 2013
    Assignee: Christian-Albrechts-Universität zu Kiel
    Inventor: Joachim Grötzinger
  • Synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders
    Patent number: 8546532
    Abstract: The instant invention comprises a process for the solid phase synthesis of directed epitope peptide mixtures useful in the treatment and diagnosis of protein conformational disorders, such process defined by a set of rules regarding the identity and the frequency of occurrence of amino acids that substitute a base or native amino acid of a known epitope. The resulting composition is a mixture of related peptides for therapeutic use. The invention also pertains to the process of generating antibodies using the directed epitope peptide mixtures as the antigens, and antibodies generated by such process, useful in the treatment and diagnostics of the said protein conformational disorder.
    Type: Grant
    Filed: April 17, 2009
    Date of Patent: October 1, 2013
    Assignee: Declion Pharmaceuticals, Inc.
    Inventors: Dustan Bonnin, Eric Zanelli, Thomas Mathers
  • Smoothened polypeptides and methods of use
    Patent number: 8546524
    Abstract: Disclosed is an isolated or purified polypeptide or peptidomimetic comprising an amino acid sequence of a portion of a Smoothened (SMO) protein, wherein the portion comprises an amino acid sequence of any of the intracellular loops of the SMO protein, a functional fragment thereof, or a functional variant of either the portion or the functional fragment, wherein the functional fragment comprises at least 7 contiguous amino acids of the intracellular loops, and wherein the functional fragment or functional variant inhibits proliferation of a diseased cell, or a fatty acid derivative thereof. Related conjugates, nucleic acids, recombinant expression vectors, host cells, and pharmaceutical compositions are further provided.
    Type: Grant
    Filed: May 14, 2012
    Date of Patent: October 1, 2013
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Nadya Tarasova, Michael Dean, Hong Lou
  • Self-assembling peptide nanoparticles useful as vaccines
    Patent number: 8546337
    Abstract: Self-assembling peptide nanoparticles (SAPN) incorporating T-cell epitopes and/or B-cell epitopes are described. The nanoparticles of the invention consist of aggregates of a continuous peptidic chain comprising two oligomerization domains connected by a linker segment wherein one or both oligomerization domains incorporate T-cell epitopes and/or B-cell epitopes within their peptide sequence. These nanoparticles are useful as vaccines and adjuvants.
    Type: Grant
    Filed: January 29, 2009
    Date of Patent: October 1, 2013
    Assignee: Alpha-O-Peptides AG
    Inventor: Peter Burkhard
  • Molecular weight markers for membrane proteins
    Patent number: 8546527
    Abstract: The present invention provides a novel membrane protein molecular weight marker.
    Type: Grant
    Filed: August 27, 2010
    Date of Patent: October 1, 2013
    Inventors: Charles Deber, Arianna Rath, Vincent G. Nadeau
  • Substrate for assaying ?-glucan and/or endotoxin and assay method
    Patent number: 8546072
    Abstract: An object of the present invention is to provide a peptide derivative for determining ?-glucan or endotoxin which allows high sensitivity measurement, and a method for determining ?-glucan and/or endotoxin using the same.
    Type: Grant
    Filed: February 20, 2009
    Date of Patent: October 1, 2013
    Assignee: Wako Pure Chemical Industries, Ltd.
    Inventors: Takeshi Kitagawa, Naoyuki Yamamoto, Mutsuhiro Date
  • Hsp9O-targeted anti-cancer chimeric peptide
    Patent number: 8546320
    Abstract: Disclosed is a substance which is not accumulated stably in cells, does not cause the dysfunction of normal cells, and so on, and therefore can be used as an anti-cancer agent or in a DDS without having any adverse side effects. It is found that Hsp90 alone cannot exhibit its function as a chaperone in assisting the refolding of a protein such as survivin, but can exhibit this function when Hop (which is one of the partner proteins of Hsp90) binds to Hsp90. Thus, specifically disclosed herein is a chimeric peptide comprising of an Hsp90 TPR domain binding peptide and a cell-penetrating peptide.
    Type: Grant
    Filed: November 13, 2009
    Date of Patent: October 1, 2013
    Assignee: Kyoto University
    Inventors: Koji Kawakami, Masayuki Kohno, Tomohisa Horibe
  • Endoplasmic Reticulum Localization Signals
    Publication number: 20130253167
    Abstract: The invention relates to cellular localization signals. In particular, the invention relates to endoplasmic reticulum localization signals in monomeric or multimeric form. The localization signals are utilized as research tools or are linked to therapeutics. Disclosed are methods of making and using polypeptides and modified polypeptides as signals to localize therapeutics, experimental compounds, peptides, proteins and/or other macromolecules to the endoplasmic reticulum of eukaryotic cells. The polypeptides of the invention optionally include linkage to reporters, epitopes and/or other experimental or therapeutic molecules. The invention also encompasses polynucleotides encoding the localization signals and vectors comprising these polynucleotides.
    Type: Application
    Filed: February 9, 2012
    Publication date: September 26, 2013
    Applicant: Intrexon Corporation
    Inventor: Thomas D. REED
  • METHOD FOR IDENTIFYING IMMUNOREACTIVE PEPTIDES
    Publication number: 20130251751
    Abstract: The invention relates to a method for identifying immunoreactive peptides. According to said method, a sample of tumorous and corresponding healthy tissue is first provided, the tumor-specific expression profile is subsequently determined and antigenic peptides are isolated from the tumorous tissue and analyzed. The respective data that has been obtained is then matched and peptides are identified on the basis of said data.
    Type: Application
    Filed: February 22, 2013
    Publication date: September 26, 2013
    Applicant: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Toni WEINSCHENK, Hans Georg RAMMENSEE
  • LIGANDS TO RADIATION-INDUCED MOLECULES
    Publication number: 20130251628
    Abstract: A method for identifying a molecule that binds an irradiated tumor in a subject and molecules identified thereby. In some embodiments, the method includes the steps of (a) exposing a tumor to ionizing radiation; (b) administering to a subject a library of diverse molecules; and (c) isolating from the tumor one or more molecules of the library of diverse molecules, whereby a molecule that binds an irradiated tumor is identified. Also provided are targeting ligands that bind an irradiated tumor and therapeutic and diagnostic methods that employ the disclosed targeting ligands.
    Type: Application
    Filed: February 13, 2013
    Publication date: September 26, 2013
    Applicant: Vanderbilt University
    Inventors: Dennis E. Hallahan, Shimian Qu, Zhaozhong Han
  • SOYBEAN APHID RESISTANCE GENE RAG2
    Publication number: 20130254945
    Abstract: Provided herein are isolated nucleic acid molecules representing a genetically defined region of the genome of the aphid resistant soybean plant (Glycine max) cultivar PI 200538 that confers resistance to soybean aphid (Aphis glycines). Within the region is a gene encoding the aphid resistance protein Rag2. Also provided herein are methods for conferring aphid resistance on a plant or enhancing aphid resistance in a plant by transforming it to contain and express such nucleic acid sequences encoding Rag2 aphid resistance or introgressing DNA encoding the trait into the plant by plant breeding. Further provided are polymorphic markers useful for identifying plant germplasm containing aphid resistance, and methods for using such markers.
    Type: Application
    Filed: September 6, 2012
    Publication date: September 26, 2013
    Applicants: United States of America as represented by the Secretary of Agriculture, THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Ki-Seung Kim, Curtis B. Hill, Glen L. Hartman, David L. Hyten, Matthew E. Hudson, Brian W. Diers, Tong Geon Lee
  • METHOD FOR PREPARING ACTIVE PEPTIDES FROM CORN GERM PROTEINS
    Publication number: 20130252877
    Abstract: The present invention discloses a method for producing antihypertensive active peptides with corn germ protein as the material. The method comprises an alkali-heat treatment and continuous enzymolysis of the corn germ protein. The components with molecular weight less than 1000 Da in the active peptides obtained according to the present method account for more than 92%, and alanine-tyrosine (Ala-Tyr, AY) as the characteristic peptide fragments in the antihypertensive peptides accounts for more than 0.6%, so that the active peptides have a good ACE inhibitory activity in vitro as well as stability against temperature, pH and major gastrointestinal digestive enzymes, and have a significant effect of lowering blood pressure on spontaneous hypertension rats in vivo. The active peptides can be applied as a new functional nutrient to development and production of food, health food and pharmaceutical.
    Type: Application
    Filed: May 14, 2013
    Publication date: September 26, 2013
    Applicant: CHINA NATIONAL RESEARCH INSTITUTE OF FOOD AND FERMENTATION
    Inventors: MUYI CAI, Ruizeng Gu, Weixue Yi, Jun Lu, Yong Ma, Zhe Dong, Yaguang Xu, Xingchang Pan, Yongqing Ma, Feng Lin, Zhentao Jin, Liang Chen, Lu Lu, Wenying Liu
  • Diagnostic Methods
    Publication number: 20130252834
    Abstract: The invention relates to a method of aiding the diagnosis of acute brain damage in a subject, said method comprising (i) assaying the concentration of at least one oxidative stress polypeptide selected from the group consisting of: PRDX1, PRDX6 and GSTP1 in a sample from said subject; and (ii) assaying the concentration of at least one further polypeptide selected from Panel A; (Hi) comparing the concentrations of (i) and (ii) to the concentrations of the polypeptides in a reference standard and determining quantitative ratios for said polypeptides; (iv) wherein a finding of a quantitative ratio of each of the assayed polypeptides in the sample to the polypeptides in the reference standard of greater than 1.3 indicates an increased likelihood of acute brain damage having occurred in said subject.
    Type: Application
    Filed: May 23, 2011
    Publication date: September 26, 2013
    Applicants: UNIVERSITE DE GENEVE, ELECTROPHORETICS LIMITED
    Inventors: Loic Gerard Dayon, Jean-Charles Sanchez, Joan Montaner Villalonga